Feb. 27, 2013
/PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that
, M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic
development programs and an overview of the company's business strategy at
10:40 am ET
Wednesday, March 6, 2013
, at the 33
Annual Cowen and Company Health Care Conference which will be held in
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under
Events and Presentations
. The presentation will be archived on the Sangamo website for two weeks after the event.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic
for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia,
's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia,
's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at
is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.